CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 99 enrolled
Drug / intervention
KRP-A218 +2 moredrug
Likely dose
itraconazole 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04908800
NCT04908800Phase 1Completed

A First-in-Human, Phase I, Double-blind, Placebo-controlled, Single and Multiple Ascending Oral Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of KRP-A218 in Healthy Subjects, Including Food-Effect and Drug-drug Interaction With Itraconazole

Kyorin Pharmaceutical Co.,Ltd·interventional·Posted Jun 1, 2021·Updated Jan 8, 2024

In Brief

A Phase 1 clinical trial evaluating KRP-A218, Placebo, and 1 other intervention for Healthy. Completed, enrolled 99 participants across 1 site.

Detailed Summary

This first-in-human study has three parts. In Parts A and B, the safety, tolerability, and pharmacokinetics (PK) will be evaluated following administration of single and multiple doses of KRP-A218, including food-effect. In Part C, the drug-drug interaction (DDI) with itraconazole will be evaluated.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited Kingdom
Collaborators--

Timeline

Phase 1CompletedFinished
20222023202420252026
First PostedJun 1, 2021
Enrollment StartMay 27, 2021
Primary CompletionApr 21, 2022
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 5.1 years ago

Interventions

KRP-A218drug

KRP-A218 tablet

Placebodrug

Placebo tablet

itraconazoledrug

10 mg/mL oral solution